AOD-9604 (hGH Fragment 176–191): The Fat Metabolism Peptide Research Guide

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide analog derived from the C-terminal fragment of human growth hormone (hGH). Specifically, it corresponds to amino acids 176–191 of the hGH sequence, with a tyrosine residue added at the N-terminus for stability. The compound was originally developed by Monash University and Metabolic Pharmaceuticals in Australia during the 1990s as a targeted fat-metabolism agent that could capture the lipolytic properties of growth hormone without triggering the insulin resistance, glucose intolerance, or anabolic side effects associated with full-length hGH.

Unlike hGH, AOD-9604 does not bind the growth hormone receptor or stimulate IGF-1 production. Its research profile is therefore narrowly focused on lipid metabolism and, more recently, cartilage and tissue repair — making it a distinctive entry in the peptide research space.

Molecular Profile

Mechanism of Action

AOD-9604's lipolytic activity appears to operate through a distinct pathway from hGH's full receptor-mediated cascade. The core mechanisms identified in preclinical and clinical research include:

Beta-3 adrenoceptor stimulation. AOD-9604 has been shown in rodent and in vitro models to activate beta-3 adrenergic receptors on adipocytes. Beta-3 receptor activation stimulates hormone-sensitive lipase (HSL), increasing the rate of triglyceride breakdown within fat cells (lipolysis). This is the same receptor subtype targeted by experimental anti-obesity drugs like mirabegron, though through a structurally different ligand.

Inhibition of adipogenesis. In vitro data indicate that AOD-9604 can suppress the differentiation of pre-adipocytes into mature fat cells. This anti-adipogenic effect appears to be mediated at least in part through downregulation of PPAR-γ (peroxisome proliferator-activated receptor gamma), a transcription factor central to fat cell formation.

No GH receptor binding. Studies using competitive binding assays confirm that AOD-9604 does not displace hGH from the GH receptor, and in rats it does not elevate serum IGF-1. This mechanistic separation from full hGH is considered its primary pharmacological distinguishing feature.

Potential chondroprotective activity. More recent in vitro and in vivo data suggest AOD-9604 may stimulate cartilage repair, possibly through TGF-β modulation. This line of research remains preliminary.

What the Research Actually Shows

Preclinical (Rodent) Fat Loss Data

The foundational animal data for AOD-9604 is reasonably robust. A series of studies from Heffernan et al. and colleagues at Monash University in the late 1990s and early 2000s demonstrated that:

• Obese male mice administered AOD-9604 subcutaneously experienced statistically significant reductions in body fat compared to controls, without changes in lean body mass.
• The effect was dose-dependent, with an inverted U-shaped response curve — very high doses were less effective than moderate doses, a pattern seen with other peptides.
• When administered alongside a high-fat diet, AOD-9604-treated mice gained significantly less adipose tissue than vehicle-treated controls, while food intake remained similar between groups.
• Unlike full-length hGH, AOD-9604 did not alter blood glucose or insulin sensitivity in these models, and did not increase tibial length (an indirect marker of IGF-1-driven bone growth).

The rodent data are internally consistent across multiple research groups, which lends them credibility — though species-to-species translation, as always, must be assumed rather than confirmed without strong human data.

Human Clinical Trials: A Complicated Record

AOD-9604 underwent a series of human trials between approximately 2000 and 2008, sponsored primarily by Metabolic Pharmaceuticals. The clinical program went through Phase I (safety), Phase IIa (proof of concept), and Phase IIb (dose-finding) trials in overweight and obese adults. Results were mixed:

Phase I: Demonstrated acceptable tolerability in healthy subjects across a range of doses (1 mg to 10 mg/day subcutaneous), with no serious adverse events attributed to the compound. No IGF-1 elevation was observed, consistent with preclinical data.

Phase IIa: A 12-week trial in 300 obese adults showed a modest, dose-dependent reduction in body fat percentage versus placebo. The effect size was statistically significant at certain doses but was considered clinically modest — approximately 1–2 kg additional fat loss over placebo.

Phase IIb/III: A larger, longer trial (the METRO study, ~900 participants over 24 weeks) failed to demonstrate statistically significant weight loss compared to placebo across the primary endpoint. This trial effectively ended AOD-9604's development as a stand-alone anti-obesity drug.

The failure at larger scale is consistent with a pattern seen in many putative lipolytic agents: effects visible in animal models or short-duration human studies do not necessarily translate into meaningful long-term clinical outcomes, possibly because fat mass is defended through multiple redundant pathways.

Oral Bioavailability Research

One unusual feature of AOD-9604's development history is that Metabolic Pharmaceuticals investigated oral formulation. Most peptides are rapidly degraded in the GI tract, but some evidence suggested that very high oral doses of AOD-9604 (around 9 mg/day) could produce measurable plasma levels. The FDA granted AOD-9604 GRAS (Generally Recognized as Safe) status for use as a food ingredient in 2014, based on safety data from the clinical program — a relatively unusual outcome for a synthetic peptide. This does not constitute approval for therapeutic use.

Cartilage and Joint Research

A separate line of preclinical investigation has examined AOD-9604 for cartilage repair. In vitro studies using human chondrocyte cultures, and some in vivo rodent models, found that AOD-9604 stimulated glycosaminoglycan synthesis and may reduce cartilage degradation markers. One small Australian clinical study evaluated AOD-9604 in knee osteoarthritis with preliminary positive results, but the study was underpowered and has not been replicated at scale. This application remains early-stage.

Comparison to Related Compounds

The key distinction of AOD-9604 within this group is its claimed IGF-1 independence and targeted adipocyte action, though this specificity did not translate into superior clinical outcomes compared to lifestyle intervention alone.

Research Limitations

The evidence base for AOD-9604 has several notable gaps:

Phase IIb failure is the dominant fact. The largest, most rigorous human trial did not meet its primary endpoint. Any use of AOD-9604 in research contexts must be interpreted against this backdrop.

Small positive trials are subject to publication bias. The positive early Phase II data existed in a context where commercial incentives aligned with reporting favorable results. The null Phase IIb result is a corrective data point that should be weighted accordingly.

Subcutaneous dosing protocols vary widely. The doses used in preclinical and clinical literature range from 100 mcg/day to 10 mg/day in humans, and there is no consensus on an optimal research protocol. Dose-response relationships are nonlinear.

Cartilage research is preliminary. In vitro and animal data on joint repair are insufficient to draw clinical conclusions. The one small human osteoarthritis study has not been replicated.

Long-term human safety data are limited. The clinical trials ran for 12–24 weeks. There are no long-term safety studies in humans.

No approved comparator trials. AOD-9604 has not been directly compared to approved weight-loss pharmacotherapy (e.g., GLP-1 agonists) in a controlled trial.

Key Takeaways

1. AOD-9604 is a synthetic C-terminal fragment of hGH (residues 176–191) designed to deliver lipolytic activity without IGF-1 stimulation or insulin resistance — properties well-supported in rodent models.
2. It activates beta-3 adrenergic receptors on adipocytes and inhibits adipogenesis via PPAR-γ suppression; it does not bind the GH receptor.
3. Early Phase I and Phase IIa human trials showed modest, statistically significant fat reduction; the larger Phase IIb/METRO trial did not confirm meaningful weight loss versus placebo.
4. The FDA has granted GRAS status to AOD-9604 as a food ingredient, based on clinical safety data — but this is not approval for therapeutic use.
5. Early preclinical and clinical data on cartilage/joint repair are intriguing but insufficient to support clinical conclusions.
6. AOD-9604's relatively clean side-effect profile in trials (no IGF-1 elevation, no glucose disruption) distinguishes it mechanistically from full-length hGH, but this mechanistic advantage did not translate into clinical efficacy at scale.
7. The compound remains an active area of research interest, particularly in tissue repair contexts, but the anti-obesity development program effectively ended after the Phase IIb failure.

This article is for informational and research reference purposes only. AOD-9604 is not approved for human therapeutic use in any jurisdiction. It is a research compound for laboratory and preclinical investigation only. Nothing in this article constitutes medical advice or a recommendation to use any compound.